Serving Overlooked PatientsSM
Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity’s global footprint is over 50 countries, with a diversified portfolio of 30+ marketed brands spanning 10 dosage forms and 10 key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. Our medicines have benefited millions of people.
PRODUCT ANNOUNCEMENT
Click for Full Prescribing Information, including Indications, BOXED WARNING, and Additional Safety Information.
PRODUCT ANNOUNCEMENT
Click for Full Prescribing Information, including Indications and Safety Information.
PRODUCT ANNOUNCEMENT
Click for Full Prescribing Information, including Indications, BOXED WARNING, and Additional Safety Information.
PRODUCT ANNOUNCEMENT
Click for Full Prescribing Information, including Indications and Safety Information.
OUR PRODUCTS
Azurity offers an ever expanding portfolio of products targeting key therapeutic areas.
News & Events
Azurity Pharmaceuticals announces the FDA Approval of XIFYRM™ (meloxicam injection) for the Management of Moderate-to-Severe Pain in Adults
FOR IMMEDIATE RELEASE Woburn, MA — June 10, 2025 — Azurity Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved XIFYRMTM (meloxicam injection) an IV non-steroidal anti-inflammatory drug (NSAID) that offers once daily dosing.
Azurity Pharmaceuticals Completes Acquisition of Covis Pharma
MEDIA ALERT: WOBURN, MA, March 14, 2025 – Azurity Pharmaceuticals (“Azurity”) announced today the successful completion of its acquisition of Covis Group S.à r.l. (“Covis”) from existing investors. With this acquisition, Covis is now a wholly-owned subsidiary of Azurity.
